Eli Lilly achieved significant revenue growth in Q2 2026, boosted by strong sales of its obesity medications. In contrast, Novo Nordisk faced challenges including price reductions and workforce reductions. Lilly is expanding its dr-g pipeline and has increased its financial outlook for the year. Novo Nordisk is working to stabilize its operations amidst pricing pressures. The upcoming year will be crucial for both companies as they navigate dr-g approvals and market strategies.
New York, New York
https://pluang.com/en/news-feed/eli-lilly-vs-novo-nordisk-pemenang-dalam-perlombaan-obat-penurun-berat-badan